Life Spine, Inc. v. Aegis Spine, Inc.

CourtDistrict Court, N.D. Illinois
DecidedMarch 17, 2020
Docket1:19-cv-07092
StatusUnknown

This text of Life Spine, Inc. v. Aegis Spine, Inc. (Life Spine, Inc. v. Aegis Spine, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Life Spine, Inc. v. Aegis Spine, Inc., (N.D. Ill. 2020).

Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION

LIFE SPINE, INC., ) ) No. 19 CV 7092 Plaintiff, ) ) v. ) Magistrate Judge Young B. Kim ) AEGIS SPINE, INC., ) ) March 17, 2020 Defendant. )

MEMORANDUM OPINION and ORDER

Plaintiff Life Spine, Inc. alleges in this diversity case that Defendant Aegis Spine, Inc. engaged in a scheme to access Plaintiff’s confidential information relating to spinal surgical products to develop its own competing products. Before the court is Defendant’s motion to dismiss Counts I and II (breach of contracts), V (breach of fiduciary duty), VI (fraudulent misrepresentation), VII (fraudulent concealment), VIII (fraudulent inducement), and X (constructive fraud) of the amended complaint. In its supporting memorandum and reply, Defendant clarifies that it does not seek to dismiss Counts VI and VIII but rather to circumscribe those claims to certain statements in the amended complaint. For the following reasons, the motion is granted in part and denied in part: Background In evaluating the current motion to dismiss, the court accepts as true the following well-pleaded facts taken from the amended complaint, drawing all reasonable inferences in Plaintiff’s favor. See Berger v. Nat’l Collegiate Athletic Ass’n, 843 F.3d 285, 289-90 (7th Cir. 2016). Plaintiff is a medical device company, specializing in spinal surgical products such as its ProLift Expandable Spacer System (“ProLift”), an implant used for patients suffering from degenerative disc

disease. (R. 45, Amend. Compl. ¶ 2.) In late 2017, Plaintiff agreed to loan or consign certain medical devices, including ProLift, to Defendant. (Id. ¶¶ 3, 11.) Defendant in turn agreed to sell Plaintiff’s devices to surgeons in a specified territory, committing to restrictions on the use and disclosure of Plaintiff’s devices and confidential information. (Id. ¶¶ 4, 23.) The parties memorialized the tenets of their relationship in three contracts. (Id.) First, the parties signed the Confidentiality Agreement (“CA”) on December

21, 2017, setting forth the terms for protecting each party’s confidential information. (Id. ¶¶ 24-26; R. 45-1, CA ¶¶ 1-9.) The CA limits the use of confidential information to the “Permitted Purpose,” or “a purpose in furtherance of a business relationship between [Plaintiff] and [Defendant],” and precludes any “use outside of such relationship.” (R. 45, Amend. Compl. ¶ 24; R. 45-1, CA ¶ 1.) The CA also requires both parties to maintain the secrecy of confidential

information and to hold it “in trust for the exclusive benefit of the Discloser.” (R. 45-1, CA ¶ 2(a).) Second, the parties executed the Loaner Agreement (“LA”) on January 4, 2018, permitting Defendant to receive Plaintiff’s devices and use them for demonstrations to potential customers, provided that Defendant “maintain[s], control[s], and properly store[s]” the loaner products and does not use such products to “reverse engineer[], copy[] or [participate in] other activities, the purpose of which is to compete with” Plaintiff. (R. 45, Amend. Compl. ¶¶ 27-28; R. 45-2, LA ¶ 3(c).) Under the LA Defendant may not transfer Plaintiff’s devices “to any other person or

entity without . . . prior written consent.” (R. 45-2, LA ¶ 3(h)(iii).) And upon request by Plaintiff, Defendant must return the loaner product within 72 hours. (Id. ¶ 3(f).) Third, the parties signed the Distribution and Billing Agreement (“DBA”) on January 25, 2018, paving the way for Plaintiff to make products available to Defendant on a trial basis and for Defendant to sell and use Plaintiff’s products and confidential information. (R. 45, Amend. Compl. ¶ 32; R. 45-3, DBA at 1.) The DBA

requires Defendant: (1) not to reverse engineer, modify, or copy any functional or design aspects of ProLift, (R. 45-3, DBA ¶ 8(b)); (2) to hold devices on a “loaned” or “consigned” basis and to return products within 72 hours upon request, (id. ¶ 3(c)); (3) to “maintain custody and/or control of each item of Inventory in a fiduciary capacity, as a trustee of [Plaintiff’s] property rights,” (id. ¶ 3(a)); (4) to promote and sell products in a specific “Territory,” (id. ¶ 2(a)); (5) to render to Plaintiff as its own

property any “work product” developed by Defendant that “involve[s] the use of [Plaintiff’s] equipment, facilities, confidential information, or trade secrets” or “relate[s] to [Plaintiff’s] current or planned business activities,” (id. ¶ 12(b)); (6) to protect Plaintiff’s confidential information, (id. ¶ 7(a), (b)); (7) to act “in accordance with the highest standards of honesty, integrity, and fair dealing,” (id. ¶ 2(b)); and (8) not to “persuade any . . . Customer[s] to use or refer patients to any Competitive Product” or make any “disparaging statements or comments to others,” (id. ¶ 8(a), (c)). (R. 45, Amend. Compl. ¶¶ 33-41.) The DBA terminates two months after “the last date that this Agreement is executed.” (R. 45-3, DBA ¶¶ 1(b), 9; R. 45-4, DBA

Addendum (reinstating and extending terms of original DBA from April 1, 2018, to May 31, 2018).) The DBA also “replace[s] all previous agreements [between the parties] relating to the same or similar matters.” (R. 45-3, DBA ¶ 15(a).) Plaintiff alleges that after the trial relationship ended, Defendant expressed an interest in executing a Stocking Distribution Agreement (“SDA”) to continue the business relationship. (R. 45, Amend. Compl. ¶ 6.) Despite reaching an agreement on the terms of the SDA in June 2019, Defendant later “abruptly refused to sign the

agreement and terminated [the] relationship.” (Id.) Then about three months later, Defendant and its corporate parent, L&K Biomed Co., Ltd. (“L&K”), a medical device company, announced their competing product AccelFix. According to Plaintiff, AccelFix is an expandable spinal implant that is “substantially identical” to ProLift. (Id. ¶¶ 7, 11, 62-64.) In fact, L&K represented to the Food and Drug Administration (“FDA”) that Plaintiff’s ProLift was the “primary predicate device”

for AccelFix and that the products are “‘substantially equivalent’ in terms of ‘use, design, function, materials used and mechanical performance.’” (Id. ¶¶ 8, 66-68.) Plaintiff alleges that it invested four years and substantial resources to research, design, develop, and test its ProLift device before obtaining FDA clearance and launching the product in March 2016. (Id. ¶ 17.) Its device contains features— such as an expansion mechanism and wand-shaped installer—that make the device unique and successful. (Id. ¶¶ 17-21.) Plaintiff claims that Defendant and L&K are “aggressively marketing” their device “in direct competition with” ProLift, causing “substantial damage” and irreparable harm. (Id. ¶¶ 9, 70.) Plaintiff also alleges

that Defendant failed to return “numerous loaned or consigned ProLift devices,” despite repeated requests. (Id. ¶ 71.) Analysis Defendant argues that dismissal is appropriate because: (1) as to Counts I and II, the DBA replaced previous agreements and, therefore, neither the CA nor the LA can form the basis for a breach of contract claim; (2) as to Counts V, VII, and X, Colorado’s economic loss doctrine bars tort claims based on a breach of

contractual duty; and (3) as to Counts VI and VIII, Plaintiff failed to plead with particularity the facts required for allegedly fraudulent statements, except for certain statements identified in Defendant’s memorandum. (R. 46, Def.’s Mot. at 1; R. 47, Def.’s Mem. at 4-12.) Plaintiff disagrees and responds that: (1) the DBA did not “nullify” the CA or the LA; (2) the law of Illinois, not Colorado, applies here and Illinois’s economic loss doctrine does not bar Counts V, VII, or X; and (3) Counts VI

and VIII should not be circumscribed to only those statements Defendant identifies. (R.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

New Hampshire v. Maine
532 U.S. 742 (Supreme Court, 2001)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Saul Catalan v. RBC Mortgage Compan
629 F.3d 676 (Seventh Circuit, 2011)
Hernandez v. Cook County Sheriff's Office
634 F.3d 906 (Seventh Circuit, 2011)
Goodyear Dunlop Tires Operations, S. A. v. Brown
131 S. Ct. 2846 (Supreme Court, 2011)
Wigod v. Wells Fargo Bank, N.A.
673 F.3d 547 (Seventh Circuit, 2012)
Moorman Manufacturing Co. v. National Tank Co.
435 N.E.2d 443 (Illinois Supreme Court, 1982)
Air Safety, Inc. v. Teachers Realty Corp.
706 N.E.2d 882 (Illinois Supreme Court, 1999)
Greer v. ADVANCED EQUITIES, INC.
683 F. Supp. 2d 761 (N.D. Illinois, 2010)
BP Amoco Chemical v. Flint Hills Resources, LLC
489 F. Supp. 2d 853 (N.D. Illinois, 2007)
Country Mutual Insurance v. Sunbeam Products, Inc.
500 F. Supp. 2d 986 (N.D. Illinois, 2007)
Medline Industries Inc. v. Maersk Medical Ltd.
230 F. Supp. 2d 857 (N.D. Illinois, 2002)
Telular Corp. v. Mentor Graphics Corp.
282 F. Supp. 2d 869 (N.D. Illinois, 2003)
Aaron McCoy v. Iberdrola Renewables, Inc.
760 F.3d 674 (Seventh Circuit, 2014)
Berger v. National Collegiate Athletic Ass'n
843 F.3d 285 (Seventh Circuit, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
Life Spine, Inc. v. Aegis Spine, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/life-spine-inc-v-aegis-spine-inc-ilnd-2020.